De Giorgi, Ugo Federico Francesco
 Distribuzione geografica
Continente #
NA - Nord America 237
EU - Europa 169
AS - Asia 150
AF - Africa 7
SA - Sud America 2
OC - Oceania 1
Totale 566
Nazione #
US - Stati Uniti d'America 232
CN - Cina 69
IT - Italia 59
SG - Singapore 38
IE - Irlanda 28
FR - Francia 14
SE - Svezia 14
BE - Belgio 11
GB - Regno Unito 9
IN - India 9
DE - Germania 8
NL - Olanda 7
ID - Indonesia 6
JP - Giappone 6
NG - Nigeria 5
CA - Canada 4
IR - Iran 4
VN - Vietnam 4
ES - Italia 3
PH - Filippine 3
PL - Polonia 3
RU - Federazione Russa 3
TR - Turchia 3
FI - Finlandia 2
IL - Israele 2
KR - Corea 2
UG - Uganda 2
AM - Armenia 1
AR - Argentina 1
AT - Austria 1
AU - Australia 1
BR - Brasile 1
CH - Svizzera 1
HK - Hong Kong 1
HU - Ungheria 1
LT - Lituania 1
MK - Macedonia 1
MX - Messico 1
MY - Malesia 1
NO - Norvegia 1
RO - Romania 1
TW - Taiwan 1
UA - Ucraina 1
Totale 566
Città #
Chandler 40
Singapore 34
Dublin 28
Santa Clara 26
Fairfield 12
Nyköping 11
Torino 9
Columbus 8
Beijing 7
Houston 7
Medford 7
Redwood City 7
Shanghai 7
Turin 7
Seattle 6
Ashburn 5
Jakarta 5
Paris 5
Princeton 5
Abuja 4
Chengdu 4
Esneux 4
Genoa 4
Hangzhou 4
Milan 4
New York 4
Pune 4
Rome 4
Calgary 3
Jiaxing 3
Madrid 3
Nanjing 3
Padova 3
Sigean 3
Tokyo 3
Wilmington 3
Wuhan 3
Bagnoli del Trigno 2
Bellingham 2
Brussels 2
Cambridge 2
Chennai 2
Düsseldorf 2
Harvard 2
Hebei 2
Hoevenen 2
Istanbul 2
Jerusalem 2
Klaaswaal 2
Parma 2
San Diego 2
St Petersburg 2
Strijen 2
Vlaardingen 2
Woodbridge 2
Zhengzhou 2
Akron 1
Americana 1
Amsterdam 1
Ankara 1
Ann Arbor 1
Arau 1
Ashiharacho 1
Bacoli 1
Bacoor 1
Bangalore 1
Borgofranco d'Ivrea 1
Boston 1
Chandigarh 1
Changsha 1
Cipolletti 1
Cluj-napoca 1
Deposit 1
Duncan 1
El Fuerte 1
Erlangen 1
Fremont 1
Frosinone 1
Gainesville 1
Guangzhou 1
Guiyang 1
Harbin 1
Hayward 1
Hefei 1
Helsinki 1
Homer 1
Homps 1
Honolulu 1
Hyderabad 1
Isfahan 1
Jacksonville 1
Kagoshima 1
Kelseyville 1
Lagos 1
Lappeenranta 1
Lianyun 1
London 1
Los Angeles 1
Lyon 1
Macerata 1
Totale 381
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 269
Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21) 65
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies 65
Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study 45
The prognostic value of pain in castration-sensitive prostate cancer 32
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society 23
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort 21
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study 20
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 16
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study 11
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA-Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial 11
Treatment Strategies for Advanced Endometrial Cancer According to Molecular Classification 4
Totale 582
Categoria #
all - tutte 2.580
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.580


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0 0 0 0 2 0 0 1 1 0 1 4
2020/202174 1 3 5 4 5 9 3 2 6 20 9 7
2021/2022100 4 11 2 11 6 5 3 5 14 3 18 18
2022/2023150 8 7 2 9 17 32 11 23 12 5 12 12
2023/2024141 20 16 6 13 7 18 3 16 7 15 6 14
2024/2025108 7 17 13 16 55 0 0 0 0 0 0 0
Totale 582